Radiopharmaceutical · Acts on CD46 (membrane cofactor protein) (CD46)
Zirconium Zr 89-DFO-YS5 is a radioimmunoconjugate in which the YS5 human IgG1 antibody is linked via desferrioxamine to the radioisotope zirconium-89. The antibody binds a conformational epitope on CD46 in Sushi domains 1 and 2, enabling PET imaging of CD46-expressing tumor cells. It is studied in bladder cancer, nerve sheath tumors and solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07664397 | Phase 1 | Bladder Cancer | Recruiting | KYNB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorBladder CancerBladder NeoplasmNerve Sheath NeoplasmsNerve Sheath TumorNerve Sheath Tumor, NosSolid CarcinomaSolid Tumor CancerSolid Tumor MalignanciesSolid Tumor NeoplasmsSolid Tumor, Adult